How soaring demand for Ozempic and Wegovy is altering Denmark's economy

Sales of the weight-loss drug Wegovy, manufactured by Novo Nordisk, have led to lower interest rates in Denmark due to an influx of US dollars into the country's economy, which has pushed up the value of the Danish krone.

cnn.com

Relevant topic timeline:

8/25/2023

Weight-Loss Drug Wegovy Will Launch In More Countries Despite Ongoing Struggles Over Stellar Demand, CEO Says

Novo Nordisk plans to launch its weight-loss drug Wegovy in more countries, despite shortages caused by high demand, according to CEO Lars Fruergaard Jorgensen.

8/28/2023

How Ozempic and Weight Loss Drugs Are Reshaping This Country’s Economy

The Danish pharmaceutical company Novo Nordisk, known for its weight loss drugs Ozempic and Wegovy, is driving most of Denmark's recent economic growth and has become the second most valuable public company in Europe.

9/1/2023

Weight loss drugmaker Novo Nordisk vies to become Europe's most valuable company, toppling LVMH

Novo Nordisk briefly surpassed LVMH to become Europe's most valuable company on the back of its weight loss drugs, but LVMH regained the top spot, although Novo Nordisk remains close behind with its highly anticipated drugs.

9/4/2023

Weight-loss drug Wegovy debuts in UK even as Novo Nordisk struggles with supplies

Novo Nordisk has launched its weight-loss injection, Wegovy, in the UK, following a controlled and limited launch, with a monthly supply priced between £199 and £299 for private patients through an online pharmacy chain.

9/6/2023

Morning Bid: Shedding pounds, buying dollars

Investors are eagerly anticipating the release of Novo Nordisk's weight-loss injection in British stores, while Manchester United shares plummeted after reports of the club being taken off the market; meanwhile, the dollar is strengthening, oil prices are rising, and concerns about weak demand and China's economy persist.

9/7/2023

Novo Nordisk Stock Jumps as JPMorgan Boosts Price Target on Obesity Drug Growth Outlook

Novo Nordisk's stock price rose by over 2% on Wall Street after JPMorgan Chase raised its price target for the company, citing a strong growth profile and potential catalysts such as positive clinical trial data for its weight-loss drug Wegovy.

Topics

Posted 8/21/2023, 3:43:00 PM